



INDEX

S. No.	Topic	Page No.
	Certificate	
	Declaration	
	Acknowledgements	
	Contents	
	List of Tables	
	List of Figures	
	List of Instruments	
	List of Chemicals	
	List of Abbreviations	
	List of Software's	
	CHAPTER 1. INTRODUCTION	1-6
1.1	Research Envisaged	2-4
1.2	Plan of Work	4-5
	<i>References</i>	6
	CHAPTER 2. LITERATURE REVIEW	7-74
2.1	Diabetes	7-8
2.1.1	Epidemiology of Diabetes	8
2.2	Alzheimer's Disease	9
2.2.1	Genomics and Proteomics of Alzheimer's Disease	9-10
2.2.2	Diabetes as Prospective Enhancer of Inflammatory Processes in Alzheimer's Disease	10-11
2.3	Blood-Brain Barrier (BBB)	11-12
2.3.1	Structure and Molecular anatomy of BBB	12-16
2.4	Strategies for Enhanced Drug Delivery to CNS	16-24
2.5	Novel Drug Delivery System Approach	24-25
2.5.1	Drug- Nanocarriers	25-29
2.5.2	Mechanism of Nanoparticle- Mediated drug Transport to the Brain	29-30
2.6	Techniques for Preparation of Nanoparticles	30-35
2.7	Stability of Nanoparticles	35-36
2.8	Nanoparticles Conjugated to Ligands in Receptor mediated Transport Systems	36-37
2.8.1	Targeted Delivery Mediated Through Transferrin Receptors	37
2.8.1.1	Transferrin	37-38
2.8.1.2	Transferrin Receptor	38-39
2.9	Nasal Anatomy and Physiology	40-42
2.9.1	Advantages of Intranasal Delivery	42

2.9.2	Demerits of Intranasal Delivery	42
2.9.3	Intranasal Delivery- A Strategy to Target CNS, Lymphatics & Perivascular Spaces of Cerebrovasculature	43-46
2.10	Intranasal Delivery of Anti-Diabetics for CNS Targeting	46
2.10.1	Formulation of Intranasal Therapeutics Agents	46-48
2.10.2	Dosage Forms for Intranasal delivery	48
2.11	Drug(s) Rationale	49-51
	<i>References</i>	52-74
CHAPTER 3. Drug & Polymer Profile		75-102
3.1	Pioglitazone HCl	75-84
3.1.1	Mechanism of Action	76-77
3.1.2	Pharmacokinetics	77
3.1.3	Pharmacokinetics Parameters	78
3.1.4	Adverse Effects	78
3.1.5	Precautions	78
3.1.6	Therapeutic Uses	78-79
3.1.7	Dose	79
3.1.8	Marketed Products	79
3.1.9	Methods of Analysis	80-84
3.2	Rosiglitazone Maleate	85-93
3.2.1	Mechanism of Action	86
3.2.2	Pharmacokinetics	86-87
3.2.3	Pharmacokinetics Parameters	87
3.2.4	Adverse Effects	88
3.2.5	Precautions	88
3.2.6	Therapeutic Uses	88
3.2.7	Dose	88-89
3.2.8	Marketed Products	89
3.2.9	Methods of Analysis	89-93
3.3	Poly (Lactic-co-glycolic acid) (PLGA)	94-100
3.3.1	Method of Manufacture	94-95
3.3.2	Description	95
3.3.3	Typical Properties of Resomer RG 503 H	95-96
3.3.4	Physical and Chemical properties of PLGA Polymers	96-99
3.3.5	Stability and Storage Conditions	99
3.3.6	Safety	99
3.3.7	Biodegradation and Toxicity of PLGA	99-100
3.3.8	Handling Precautions	100
3.3.9	Applications in Pharmaceutical Technology	100
	<i>References</i>	100-104

CHAPTER 4. PREFORMULATION		105-134
4.1	Drug sample(s)	105
4.2	Preparation of Rosiglitazone base	105-106
4.3	Drug identification	106
4.3.1	Physical appearance	106
4.3.2	Melting point	106
4.3.3	Solubility studies	106-107
4.3.4	FTIR-Spectroscopic studies	107
4.3.5	UV-spectroscopic studies	107-108
4.3.5.1	Ultraviolet Absorption Maxima (λ_{max}) of Pioglitazone HCl	108
4.3.5.2	Ultraviolet Absorption Maxima (λ_{max}) of Rosiglitazone maleate and Rosiglitazone base	108-109
4.3.6	Partition Coefficient	109
4.4	Analytical methods	109
4.4.1	Calibration curve of Pioglitazone HCl in Methanol: Acetonitrile (1:1)	109-110
4.4.2	Calibration curve of Pioglitazone HCl in Methanol: Acetonitrile: PBS (pH 7.4): 0.1 N Sodium hydroxide solution (1:1:1:7)	110
4.4.3	Calibration curve of Rosiglitazone maleate in Methanol	111
4.4.4	Calibration curve of Rosiglitazone base in Acetonitrile: PBS (pH 7.4) (2:3)	111-112
4.4.5	Accuracy	112
4.4.6	Precision	112
4.4.7	Linearity	112-113
4.4.8	Stability and selectivity	113
4.5	Results and discussion	130-133
	<i>References</i>	134
CHAPETR 5. PREPARATION & CHARACTERIZATION		135-204
5.1	Preparation of PLGA nanoparticles	139
5.1.1	Nanoprecipitation Method	139-140
5.1.1.2	Optimization	140
5.1.3	Emulsion Solvent Evaporation Method	149-150
5.1.4	Optimization	150
5.2	Transferrin conjugation to nanoparticles	161
5.3	Nasal Solution	161
5.3.1	Nasal solution of Pioglitazone HCl	161
5.3.2	Nasal solution of Rosiglitazone maleate	162
5.4	Characterization of nanoparticles	162
5.4.1	Particle Size Measurement	162-163
5.4.2	Zeta Potential	163
5.4.3	Drug Content	163-164

5.4.4	FTIR Spectroscopy	164
5.4.5	Morphology	164
5.4.6	Thermogravimetric Analysis (TGA)	164-165
5.4.7	X-ray Diffraction (XRD)	165
5.4.8	<i>In vitro</i> Drug Release from Nanoparticles	165-166
5.5	Lyophilization and optimization of cryoprotectant concentration	166-167
5.6	Results and Discussion	182
5.6.1	Optimization of formulation variables for the preparation of nanoparticles	182-183
5.6.1.1	Nanoprecipitation method	183-190
5.6.1.2	Emulsion solvent evaporation method	190-192
5.6.2	Transferrin conjugation to nanoparticles	192-193
5.6.3	Characterization of PLGA nanoparticles	193
5.6.3.1	Particle Size Measurement	193
5.6.3.2	Zeta potential	193
5.6.3.3	Drug Content	193-194
5.6.3.4	FTIR Spectroscopy	194-195
5.6.3.5	Morphology	195
5.6.3.6	Thermogravimetric Analysis (TGA)	195-197
5.6.3.7	X-Ray diffraction (XRD)	197-198
5.6.3.8	<i>In Vitro</i> Drug Release from Nanoparticles	198-199
5.6.4	Lyophilization and optimization of cryoprotectant concentration	199-201
5.7	Conclusion	201-202
	<i>References</i>	203-204
CHAPTER 6. STABILITY STUDIES		205-222
6.1	Methodology	207
6.1.1	Effect of Storage on Appearance	207
6.1.2	Effect of Storage on Particle Size & PDI	207-208
6.1.3	Effect of Storage on Zeta Potential	208
6.1.4	Effect of Storage on Percent Residual Drug Content	208
6.2	Results and Discussion	217
6.2.1	Effect on Appearance	217-218
6.2.2	Effect of Storage on Particle Size & PDI	218-219
6.2.3	Effect of Storage on Zeta Potential	219
6.2.4	Effect of Storage on Percent Residual Drug Content	219-220
6.3	Conclusion	220-221
	<i>References</i>	222
CHAPTER 7. EX-VIVO STUDIES		223-244
7.1	Hemolytic toxicity study	223-224

7.2	MTT cytotoxicity assay	224-228
7.3	Results and discussion	234-241
7.4	Conclusion	241
	<i>References</i>	243-245
	CHAPTER 8. IN-VIVO STUDIES	246-285
8.1	Radiolabelling of nanoparticle formulation	247-248
8.2	Radiolabelling efficiency & radiochemical purity	249
8.3	Optimization of radiolabeling process	250
8.4	Biodistribution Study of ^{99m} Tc labelled Pioglitazone/ Rosiglitazone formulations	251-252
8.5	Results and discussion	273
8.5.1	Radiolabelling of Nanoparticulate Formulations	273-274
8.5.2	Biodistribution Study of ^{99m} Tc Labeled Formulations	274-281
8.6	Conclusion	281-282
	<i>References</i>	283-285
	CHAPTER 9. SUMMARY & CONCLUSION	286-308